As of 2024-12-14, the Relative Valuation of Xbrane Biopharma AB (XBRANE.ST) is (3.76) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 0.17 SEK, the upside of Xbrane Biopharma AB based on Relative Valuation is -2357.7%.
The range of the Relative Valuation is (3.88) - (4.82) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.0x - 21.1x | 18.6x |
| Forward P/E multiples | 5.1x - 19.9x | 12.5x |
| Fair Price | (3.88) - (4.82) | (3.76) |
| Upside | -2426.8% - -2993.9% | -2357.7% |
| Date | P/E |
| 2024-11-28 | -0.75 |
| 2024-11-27 | -0.73 |
| 2024-11-26 | -0.73 |
| 2024-11-25 | -0.76 |
| 2024-11-22 | -0.79 |
| 2024-11-21 | -0.82 |
| 2024-11-20 | -0.84 |
| 2024-11-19 | -0.89 |
| 2024-11-18 | -0.81 |
| 2024-11-15 | -0.84 |
| 2024-11-14 | -0.80 |
| 2024-11-13 | -0.83 |
| 2024-11-12 | -0.82 |
| 2024-11-11 | -0.85 |
| 2024-11-08 | -0.84 |
| 2024-11-07 | -0.87 |
| 2024-11-06 | -0.86 |
| 2024-11-05 | -0.92 |
| 2024-11-04 | -0.92 |
| 2024-11-01 | -0.93 |
| 2024-10-31 | -0.97 |
| 2024-10-30 | -0.98 |
| 2024-10-29 | -0.95 |
| 2024-10-28 | -0.97 |
| 2024-10-25 | -0.87 |
| 2024-10-24 | -0.85 |
| 2024-10-23 | -0.81 |
| 2024-10-22 | -0.84 |
| 2024-10-21 | -0.89 |
| 2024-10-18 | -0.74 |
| 2024-10-17 | -0.71 |
| 2024-10-16 | -0.74 |
| 2024-10-15 | -0.74 |
| 2024-10-14 | -0.72 |
| 2024-10-11 | -0.80 |
| 2024-10-10 | -0.85 |
| 2024-10-09 | -0.86 |
| 2024-10-08 | -0.80 |
| 2024-10-07 | -0.77 |
| 2024-10-04 | -0.75 |
| 2024-10-03 | -0.75 |
| 2024-10-02 | -0.77 |
| 2024-10-01 | -0.76 |
| 2024-09-30 | -0.80 |
| 2024-09-27 | -0.80 |
| 2024-09-26 | -0.74 |
| 2024-09-25 | -0.74 |
| 2024-09-24 | -0.65 |
| 2024-09-23 | -0.65 |
| 2024-09-20 | -0.64 |